A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR positive myasthenia gravis (DAS-MG)

Neurology & Rehabilitation Medicine

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects

Principal Investigator(s)

Dr. Henry Kaminski

Request Information

First Name

Last Name

Email Address

Confirm email

Phone Number

Address

Address 2

City/Town

State/Province

ZIP/Postal Code

Comments / Questions

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Clinical Trials

Nasal Microbiome and Immune System Environment in Response to Intra-Nasal Live-Attenuated Influenza Vaccine

Infectious Diseases

In this study, we hope to better understand how the bacteria living in your nose (called the nasal microbiome) interacts with the local immune system, and also how those may impact the immune response to live-attenuated influenza vaccine (LAIV) (e.g., nasal spray flu vaccine).

Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors

Cancer & Blood Disorders

Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors

View All Clinical Trials

The GW Office of Clinical Research (GW OCR) serves as a resource for faculty and staff involved in clinical and translational research.

Visit the GW Office of Clinical Research

Visit the GW School of Medicine and Health Sciences Office of Research